Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.84 |
| ▸ | HTT | P42858 | 2/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.84 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.84 |
| ▸ | TUBB | P07437 | 2/20 | 0.84 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.84 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.84 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.84 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.84 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.84 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.84 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.84 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.84 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.84 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.84 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nocodazole SCHEMBL29360101 | 1.00 | ABL1 (0.84) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8009081 | 1.00 | ABL1 (0.84) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL7615542 | 0.99 | ABL1 (0.82) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8198291 | 0.96 | ABL1 (0.77) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8195415 | 0.96 | ABL1 (0.77) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL22418403 | 0.95 | ABL1 (0.76) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL29573963 | 0.91 | ABL1 (1.00) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL2324427 | 0.91 | ABL1 (1.00) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8186933 | 0.90 | ABL1 (0.68) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| SCHEMBL4204424 | 0.87 | NPC1 (0.64) | ABL1ALDH1A1LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 30069 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144890-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY | MyricX Pharma Limited (GB) | 2026-05-28 | — | — | US | claimed |
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2026-05-14 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4720329-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SensID GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260090990-A1 | DRUG DELIVERY SYSTEM | LIPOGEMS INT S P A (IT) | 2026-04-02 | — | — | US | claimed |
| EP-4713438-A2 | COMPOSITIONS AND METHODS FOR MULTIPLEX ENGINEERING OF IMMUNE CELLS | Be Biopharma, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260028596-A1 | METHOD FOR PRODUCING HIGH YIELD AND HIGH QUALITY RECOMBINANT ADENO-ASSOCIATED VIRUS | AAVATAR THERAPEUTICS CO LTD (KR) | 2026-01-29 | — | — | US | claimed |
| EP-4680284-A2 | BIODEGRADABLE DENDRITIC PARTICLES FOR SUSTAINED DRUG RELEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-01-21 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| WO-1996006863-A1 | AGENTS FOR INDUCING APOPTOSIS AND APPLICATIONS OF SAID AGENTS IN THERAPY | UNIVERSITY OF DUNDEE (GB) | 1996-03-07 | — | — | WO | claimed |
| US-5480772-A | SEPARATION OF NUCLEUS FROM ERYTHROCYTES USING PROTEASE AND NONIONIC DETERGENTS, CONTACTING WITH CYTOSTATIC FACTOR EXTRACT AND PRETREATMENT WITH ACTIVATING EGG EXTRACT | BRANDEIS UNIVERSITY (US) | 1996-01-02 | — | — | US | claimed |
| EP-0686202-A1 | PRENATAL SCREENING | BRANDEIS UNIVERSITY (US) | 1995-12-13 | — | — | EP | claimed |
| EP-0663958-A1 | INHIBITION OF CYST FORMATION BY CYTOSKELETAL SPECIFIC DRUGS | Woo, David D.L. (US) | 1995-07-26 | — | — | EP | claimed |
| WO-1994018344-A1 | PRENATAL SCREENING | BRANDEIS UNIVERSITY (US) | 1994-08-18 | — | — | WO | claimed |
| WO-1994008041-A1 | INHIBITION OF CYST FORMATION BY CYTOSKELETAL SPECIFIC DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-04-14 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0251760-B1 | Rubber composition | BRIDGESTONE CORP (JP) | 1994-01-26 | — | — | EP | claimed |
| US-5140055-A | Improved high speed grip performance | BRIDGESTONE CORPORATION (JP) | 1992-08-18 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |